Transforming growth factor beta receptor II (TGFBR2) (TGFBR2)

Transforming growth factor beta receptor II (TGFBR2) is a transmembrane serine/threonine kinase that serves as a critical component of the TGF-beta signaling pathway [1, 8]. Upon binding to its dimeric ligands (TGF-beta 1, 2, or 3), TGFBR2 recruits and phosphorylates the type I receptor (TGFBR1), initiating a signaling cascade that primarily involves the phosphorylation of SMAD proteins [4, 10]. This pathway regulates a wide array of cellular processes, including proliferation, differentiation, apoptosis, and extracellular matrix production [9, 13]. In healthy tissues, TGF-beta signaling acts as a potent tumor suppressor; however, in advanced cancers, it often switches to a pro-tumorigenic role, promoting epithelial-mesenchymal transition (EMT), metastasis, and immune evasion [10, 11]. Consequently, TGFBR2 and its ligands are major therapeutic targets in oncology and fibrotic diseases [2, 15]. Therapeutic strategies include monoclonal antibodies that neutralize the ligands, ligand traps that sequester TGF-beta, and small-molecule inhibitors that block the receptor's kinase activity [1, 15]. Despite their potential, clinical development has faced challenges such as on-target toxicities, including cardiotoxicity and the development of benign skin lesions [5, 11].

Other names

TGF-beta receptor type IITbetaR-IITGFR-2TGF-beta receptor type 2Transforming growth factor-beta receptor type IITGF-beta 1TGF-beta 2TGF-beta 3

Inhibition of ligand-receptor binding through neutralizing antibodies or ligand traps, and inhibition of receptor kinase activity using small molecule inhibitors to block downstream SMAD-dependent and SMAD-independent signaling.